SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings and guidance are the main focus, with traders watching for signs that engagement, subscriber growth and advertising can offset concerns about content quality, recent layoffs and the content leadership change. Views are split between traders bracing for another post-earnings drop and bulls arguing that pessimism is already reflected in the share price.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is tied to enthusiasm for its Merck-partnered personalized melanoma vaccine after positive Phase 3 topline results, with traders focused on the detailed data presentation at ESMO. Bulls see validation of a broader cancer-vaccine platform and momentum, while bears argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Traders are citing a reported ClinicalTrials.gov update adding a site to Sareptas ENHANCE Elevidys safety study as a possible trigger for the rebound, though they note the study timeline reportedly slipped. The broader debate centers on whether upcoming DM1 and FSHD data can support a recovery, with some traders pointing to short covering and others stressing that those clinical results remain unproven.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plans to pursue a public listing for fintech arm Monee and launch Sea Cloud are fueling concern about spending and uncertainty. Traders largely blame the developments for the selloff, while some see a Monee listing as a potential way to unlock value for shareholders.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and higher outlook have been met with a sharp selloff, prompting traders to question why strong demand and orders are not lifting the shares. The debate centers on rising costs, weaker cash conversion and an insurance loss, while some investors view the reaction as excessive given the improved guidance.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention after its quarterly earnings beat and improved cash-flow outlook failed to prevent a sharp selloff, as traders focused on narrowed full-year profit guidance with no increase to its midpoint. Some see the new buyback and cash generation as support for the shares, while others argue the outlook disappointed despite the strong quarter.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash proceeds as a potential balance-sheet and strategic reset. Others argue the divestiture removes a significant revenue stream and leaves concerns about debt and weakness in the remaining business; the transaction is still pending approval and closing.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

A sharp COMP rally and stronger volume have fueled talk of a technical reversal, with traders pointing to chart patterns and a possible breakout. Bulls see renewed momentum, while skeptics question whether the move can hold given COMPs history of lagging other crypto assets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Upcoming MSToronto clinical presentations are driving attention, especially initial Phase 1 azer-cel results in progressive MS alongside BRIUMVI data on long-term outcomes and dosing. Traders are broadly optimistic about the catalyst-rich pipeline and BRIUMVIs commercial growth, while some caution that azer-cel is early-stage and debate the stocks muted trading; buyout speculation remains unconfirmed.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports shares are drawing attention after RAP-219s Phase 2 bipolar-mania trial met its primary and secondary endpoints, prompting bullish reactions and analyst upgrades. Traders are debating whether the efficacy signal is strong enough to justify the surge, citing the modest placebo-adjusted improvement, higher discontinuation rate, and the stocks sharp retreat after its initial jump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million.
PDS Biotechnology (NASDAQ:PDSB) shares movedread more...

HeartBeam Gets FDA Breakthrough Designation

HeartBeam (NASDAQ:BEAT) scored a significant regulatory catalyst as the U.S. FDA granted Breakthrough Device Designation to the HeartBeam System for its potential use in assessing suspected heart attacks outside the hospital. The designation gives the company prioritized interaction with the FDA as it works toward a pivotal study and potential expansion of the device’s indication.

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the HeartBeam System as a tool for assessing...

HeartBeam, Inc. Letter to Shareholders

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today issued a letter to shareholders from its Executive Chairman Richard Ferrari, and President and Founder, Branislav Vajdic, PhD. Dear Fellow Shareholders...

HeartBeam Reports Second Quarter 2026 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2026. Second Quarter & Subsequent 2026 Operational Highlights In...

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2026, and will be...

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-sized, cable-free ECG device. The patent covers...

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach. 

This account has been verified as an official BEAT representative.

Verified Account

HeartBeam, Inc. Account

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

HeartBeam Inc

Why Did BEAT Stock Rocket 72% In Pre-Market Today? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.</li><li>The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.</li><li>The company intends to roll out a controlled commercial launch in early 2026.</li></ul>HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.<h2 class="st-heading-2">Why It Matters?</h2>Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BEAT">HeartBeam’s stock</a> traded over 72% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day, while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<blockquote>“We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”-Robert Eno, CEO, HeartBeam</blockquote><h2 class="st-heading-2">Limited U.S. Launch Planned</h2>The company intends to roll out a controlled commercial launch in early 2026, targeting select concierge and preventive cardiology groups that have expressed strong interest.&nbsp;It has developed a working prototype of an extended-wear 12-lead ECG patch, designed to provide continuous cardiac monitoring. As HeartBeam’s 3D ECG platform adoption grows, the resulting data repository will enable longitudinal analysis. The company plans to use this data to develop AI-based screening and predictive algorithms.BEAT stock has lost over 64% in 2025 and over 73% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-signals-tough-road-ahead-amid-slumping-ev-demand-ceo-says-there-is-a-slowdown-there-s-no-question-about-it/cLIHRZWRENx">Lucid Signals Tough Road Ahead Amid Slumping EV Demand: CEO Says ‘There Is A Slowdown, There’s No Question About It’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atrial tachycardia electrocardiogram, heart rhythm disorder where the patient complains of rapid palpitation sensations.

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$0.4147
Prev Close	$0.413
Open	$0.4108
Dividend Yield	0.00%
50-Day Moving Average	$0.4564
Beta	1.32
Avg. Volume	414,446.32
PE Ratio	-0.81

52-Week High	$4.00
52-Week Low	$0.355
Market Capitalization	$23.27M
EPS (Annual)	-$0.6234
Price to Book	2.85
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BEAT Fundamentals